Novo Nordisk · 10 hours ago
Internship - Omnichannel Intelligence and Optimization
Plainsboro, NJ
Internship
Onsite
Intern
$52K/yr - $89K/yrNovo Nordisk is a global pharmaceutical company focused on creating human-centered experiences for patients. The Omnichannel Intelligence and Optimization intern will gain hands-on experience by analyzing marketing performance data to identify insights and optimization opportunities, assisting the team in enhancing marketing initiatives.
BiotechnologyHealth CareMedicalPharmaceutical
No H1B
Responsibilities
Learn more about omnichannel analytics and deep diving into marketing performance data to identify insights and optimization opportunities
Assist the team in fine tuning marketing initiatives to create cost efficiencies, increase reach, and optimize customer engagement
Qualification
Required
Must be a current student enrolled or recently graduated (graduation date no earlier than April 2026) at/from an accredited college or university pursuing at least a bachelor's degree
Strong academic record with a preferred cumulative GPA of 3.0 or higher
Conscientious self-starter with good organizational skills, project management skills and attention to detail
Ability to balance multiple projects and priorities, must be able to multi-task
Strong interpersonal communication and ability to collaborate with teams; must effectively operate independently, across functional lines, and with internal customers
Demonstrated personal initiative, self-motivation, flexibility, adaptability and willingness to learn
Proficient in Microsoft Office Tools including Word, Excel, PowerPoint, etc
Preferred
A completed or in progress undergraduate degree in Marketing Analytics, Business Intelligence, Computer Science, Data Analytics or a related discipline preferred
Class year of a freshman or sophomore preferred
Company
Novo Nordisk
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
Founded in 1923
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$22M2018-12-05Post Ipo Equity· $22M
1981-07-09IPO
Leadership Team
Lars Fruergaard Jørgensen
President and CEO
Lars Sorensen
President & CEO
Recent News
Labiotech UG
2026-01-24
bloomberglaw.com
2026-01-24
Company data provided by crunchbase